Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 5, 2001, Pages 356-360

  Mukohara, Toru ^a   Takeda, Koji ^a   Miyazaki, Masaki ^a   Takifuji, Nobuhide ^a   Terakawa, Kazuhiko ^a   Negoro, Shunichi ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Low dose docetaxel; Non small cell lung cancer (NSCLC); Second line chemotherapy

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TAXOIDS;

EID: 0034759018     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100362     Document Type: Article

References (22)

1. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
2. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
3. Single agents in the second-line treatment of non-small cell lung cancer
4. Phase II trials of taxotere in patients with non-small cell lung cancer
5. Single-agent docetaxel in patients with refractory non-small-cell lung cancer
6. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
7. 2 versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy regimen
8. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Result of a phase II multicenter trial
9. Cancer of the lung
10. Chemotherapy of lung cancer
11. Chemotherapy for unresectable non-small cell lung cancer
12. Nonparametric estimation from incomplete observations
13. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: A Japanese cooperative study
14. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer
15. Chemotherapy in non-small cell lung cancer: A meta-analysis using updates on individual patients from 52 randomised clinical trials
16. Chemotherapy can prolong survival in patients with non-small cell lung cancer: Report of Canadian multicenter randomized trial
17. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
18. Phase II study of docetaxel (taxotere) in first- and second-line NSCLC
19. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
20. Phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug
21. Toxicity grading criteria of the Japan Clinical Oncology Group